Current Evidence of the Efficacy and Safety of Neoadjuvant EGFR-TKIs for Patients With Non-small Cell Lung Cancer

Current Evidence of the Efficacy and Safety of Neoadjuvant EGFR-TKIs for Patients With Non-small Cell Lung Cancer

PurposeEpidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been indicated to be an effective treatment for advanced EGFR-mutant NSCLC. However, the neoadjuvant application of EGFR-TKIs in resectable NSCLC needs further investigation. Here, we aimed to evaluate the efficacy a...

Full description

Bibliographic Details
Main Authors: Xiaoshun Shi, Xiaoying Dong, Jianxue Zhai, Xiguang Liu, Di Lu, Zhen Ni, Hua Wu, Kaican Cai
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-05-01
Series:Frontiers in Oncology
Subjects:
neoadjuvant therapy
EGFR-TKI
meta-analysis
NSCLC
surgery
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.608608/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.608608/full

Similar Items